Medicare Compliance & Reimbursement
Ad Rules: Drug Makers Doing It For Themselves
Critics question appropriateness of PhRMA making DTC ad guidelines. The document also reports PhRMA plans to set up a telephone hot line and monitoring office to address complaints about DTC prescription drug ads.
The trade association that represents most of the country's leading drug makers unveiled a document it says will act as a compass for companies advertising products to consumers. But critics made it immediately clear that they'd sooner leave a fox in charge of a sheep herd than let the pharmaceutical industry police itself.
On August 2, the Pharmaceutical Research and Manufacturers of America released "PhRMA Guiding Principles Direct to Consumer Advertisements About Prescription Medicines," a list of 15 "guiding principles" that PhRMA wants its drug making clients to adopt in order to keep their direct-to-consumer advertising in line with Food and Drug Administration regulations.
"DTC advertising of such important and powerful products as prescription drugs should be responsibly designed to achieve these goals, and to encourage the appropriate use of these products," according to the PhRMA report.
PhRMA CEO Billy Tauzin stressed that these guidelines were voluntary, but 23 companies have already committed to following them. According to Tauzin, Bristol-Myers Squibb, GlaxoSmithKilne, Eli Lily and Co., Johnson & Johnson and Bayer Healthcare AG are among the companies that have already agreed to follow the rules.
These guidelines "are a significant step in the right direction," said Peter R. Dolan, CEO of Bristol-Myers Squibb and chairman-elect at PhRMA.
According to the guidelines, drug makers' DTC advertising should always:
"Patients need accurate and timely information, and should be encouraged to discuss diseases and treatment options with physicians. These principles will help us reach that goal," said Tauzin.
Those opposed to a pharmaceutical trade association leading DTC advertising governance lined up immediately to offer their takes on the announcement. Leading the way was Sen. Chuck Grassley (R-IA), who released a statement the same day PhRMA made its guidelines public.
This announcement "doesn't deliver a single guarantee for consumers," Grassley said in a statement. "The FDA needs to stop dragging its feet and start exercising its authority to closely monitor the marketing of pharmaceuticals.
"It doesn't make sense to rely on drug companies to police themselves."
Grassley has been a leading critic of DTC ads for years. In April, he co-sponsored of a bill that would, among other things, set up a new drug safety office within the FDA and require drug makers to submit ads to the FDA for approval.
Medicare Compliance & Reimbursement
- MEDICARE ADVANTAGE:
A Dream Deferred- Regional PPO Plans Face Obstacles
Many won't be able to comply until 2007.
Health plan providers see great possibilities in the [...] - HOSPITALS:
Ambulance Services Added To Billing Duties
Independent contractors will look to facility for reimbursement.
When an ambulance transports an inpatient between his [...] - PHYSICIANS:
CMS Pushes Self-Referral Ban For PET Scans
Nuclear medicine also on chopping block.
Physicians could have a much harder time performing PET scans [...] - PHYSICIANS:
Medicare Offering Exemption Waivers
Burden on provider to prove patient hardship.
A new proposal might play a big role in [...] - PHYSICIANS:
Brakes Applied To Drug Bidding Program
Drugs may be available through vendors by July 2006.
The Centers for Medicare and Medicaid Services [...] - REHAB:
Live Appeals Hearings Headed Toward Extinction
Expert fret over rule change that may damage appeal chances.
Under the new appeals system, adjudicators [...] - REHAB:
Rule Reduces IRF Outlier Thresholds
...but it will also cut standard payments.
Good news for inpatient rehab facilities: The Centers for [...] - LONG-TERM CARE:
Providers Get Ready: New Pay System Starting Soon
Feds show no signs of slowing new PPS implementation.
Long-term care providers should not let early [...] - LONG-TERM CARE:
Hello QIO? Providers Can Profit From A Call
'8th Scope Of Work' now underway.
Providers that are looking for a way to edge ahead [...] - ENFORCEMENT WATCH:
Bad Consultants Are The Clinic's Problem, Too
Physical therapy clinics come under fire for Medicare and Medicaid fraud.
Physical therapy providers should only [...] - PHARMACEUTICALS:
Ad Rules: Drug Makers Doing It For Themselves
Critics question appropriateness of PhRMA making DTC ad guidelines.
The trade association that represents most of [...] - BILL WATCH
The following bills were introduced in the House: H.R. 3423. A bill to amend the [...]
